Article

VIDEO: Thomas Stinchcombe, MD, Discusses the Treatment of Non-Small Cell Lung Cancer

Conference|NAMCP: National Association of Managed Care Physicians Forum

Thomas Stinchcombe, MD, assistant professor of clinical research, UNC Lineberg Comprehensive Cancer Center, discusses the treatment of patients with non-small cell lung cancer (NSCLC).

Thomas Stinchcombe, MD, assistant professor of clinical research, UNC Lineberg Comprehensive Cancer Center, discusses the treatment of patients with non-small cell lung cancer (NSCLC). In order to manage cost, Dr Stinchcombe says that molecular testing allows clinicians to pick the correct treatment for the patient.

This video was taken on November 8 at the NAMCP Fall Managed Care Forum in Las Vegas, NV.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Related Content
Oncology Research | Image credit: iStock
January 30th 2025

Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event

Mary Caffrey
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
Image of Managed Care Cast logo
August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

Maggie L. Shaw
At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Two abstracts presented at ASH 2024 provided insight into MDS response to hypomethylating agents (HMAs) | Image credit: Sviatlana - stock.adobe.com
January 19th 2025

Exploring Response to HMAs for MDS Across Various Patient Types

AJMC Contributor
Two abstracts presented at the 2024 American Society of Hematology Annual Meeting & Exhibition provided insight into MDS response to hypomethylating agents (HMAs).
Managed Care Cast.
June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia
On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
chronic lymphocytic leukemia | Image credit: LASZLO – stock.adobe.com
January 15th 2025

BTKi Resistance Mechanisms, Solutions Probed at ASH

Jared Kaltwasser
One study found most—but not all—patients with chronic lymphocytic leukemia disease progression while taking a Bruton tyrosine kinase inhibitor (BTKi) had a key mutation linked to resistance.
Marie-France Jilderda, MD, PhD Candidate Surgical Oncology at Leiden University Medical Center in the Netherlands.
January 15th 2025

BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer

Cameron Santoro
The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo